- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- TORRENT PHARMA
TORRENT PHARMA Share Price 
(TORR)
Here is the latest stock price and chart of Torrent Pharma. For more details, see the Torrent Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Oct 19, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)1,563.35 | Open (Rs) 1,556.15 | High (Rs) 1,576.95 | Low (Rs) 1,515.90 |
| % Change0.23 | Volume 11,697 | Value (Rs) 18,101,886 | 52-Week H/L 1,871.95 / 1,206.00 |
| Live NSE Quotes | Oct 19, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)1,562.80 | Open (Rs) 1,558.90 | High (Rs) 1,578.00 | Low (Rs) 1,511.35 |
| % Change0.12 | Volume 243,809 | Value (Rs) 377,817,918 | 52-Week H/L 1,872.80 / 1,204.20 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 38.58 | P/E Ratio (x) 40.52 | Market Cap (Rs m) 264,612.62 | P/BV (x) 5.72 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
TORRENT PHARMA Share Price Today:
TORRENT PHARMA last traded price was up 0.2% to Rs 1,563.4 on the BSE. On the NSE, TORRENT PHARMA last traded price was up 0.1% to Rs 1,562.8. The total volume of shares traded was 0.3 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.6%. And the benchmark S&P BSE SENSEX was at 34,315.6 (down 1.3%).
Over the last 30 days, the TORRENT PHARMA share price is down 10.9%. And over the last one year, TORRENT PHARMA share price is up 15.2%.
|
| |
Today's Market
Sensex Ends Over 450 Points Lower; IT and Energy Stocks Witness Selling(Closing)
Share markets in India continued their sell-off seen during the day and ended the trading session deep in the red. All sectoral indices traded on a negative note with stocks in the IT sector.
Related Views On News
TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)
Aug 6, 2018 | Updated on Aug 6, 2018For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)
Jun 1, 2018 | Updated on Jun 1, 2018For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)
Oct 8, 2018While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.
My Top 3 Tips to Navigate the Market Crash(The 5 Minute Wrapup)
Oct 8, 2018Steep corrections are never easy to handle. It's hard to watch the value of your shares drop so much. But you can take steps to make the most of it.
IPO Market Feels the Heat of the Market Crash(Sector Info)
Oct 12, 2018The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.
Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)
Oct 12, 2018Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.
ICICI Prudential Manufacture In India Fund: A Make In India Prodigy, Should You Invest?(Outside View)
Oct 8, 2018PersonalFN briefly explains if you should be investing in the NFO: ICICI Prudenetial Manufacture in India Fund.
MoreTRACK TORRENT PHARMA
- Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON TORRENT PHARMA
TORRENT PHARMA 5-YR ANALYSIS
COMPARE TORRENT PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.